CMRX - CHIMERIX INC
Region: US
Website: chimerix.com
Employees: 90
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Chimerix, Inc. develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]
Read moreExploring US High Growth Tech Stocks In March 2025
In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.
Read moreChimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025
We recently published a list of the 11 Best Performing Stocks So Far In 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against the other best performing stocks so far in 2025. On March 21, Jason Pride, Chief of Investment Strategy at Glenmede, and Stephen DeNichilo, […]
Read more